Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 26, 2022, in connection with the transactions contemplated by the Business Combination Agreement, dated December 22, 2021, by and among Ortho Clinical Diagnostics Holdings plc (the "Company"), Quidel Corporation, Coronado Topco, Inc. ("Topco") and the other parties thereto (the "BCA"), the Company entered into an Option Agreement Amendment (the "Amendment") with Michael S. Iskra, the Company's Executive Vice President of Commercial Excellence and Strategy. Pursuant to the Amendment, Mr. Iskra's unvested options will vest on July 1, 2022, subject to Mr. Iskra's continued employment by the Company (or Topco following the consummation of the transactions contemplated by the BCA) through such date. Additionally, in the event that Mr. Iskra's employment is terminated by the Company without cause, then all his unvested options will vest.

The foregoing description of the Amendment with Mr. Iskra does not purport to be complete and is qualified in its entirety by reference to the text of the Amendment, which is filed as Exhibit 99.1to this Current Report on Form 8-K and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.


Exhibit    Description
Number
99.1        Option Agreement Amendment, dated May 26, 2022, between Michael Iskra
          and the Company
104       Cover Page Interactive Data File (embedded within the Inline XBRL
          document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses